Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 2/20 | 0.39 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.39 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
| ▸ | GPR65 | Q8IYL9 | 4/20 | 0.34 |
| ▸ | HTR2A | P28223 | 2/20 | 0.33 |
| ▸ | HTR6 | P50406 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30296325 | 1.00 | CHRNA7 (0.39) | CHRNA7CHRNB2CHRNA4SIGMAR1GPR65 | |
| SCHEMBL24571034 | 1.00 | CHRNA7 (0.39) | CHRNA7CHRNB2CHRNA4SIGMAR1GPR65 | |
| SCHEMBL26880619 | 1.00 | CHRNA7 (0.39) | CHRNA7CHRNB2CHRNA4SIGMAR1GPR65 | |
| SCHEMBL30391461 | 0.80 | CHRNA7 (0.36) | CHRNA7CHRNB2CHRNA4SIGMAR1HTR2A | |
| SCHEMBL30296275 | 0.80 | CHRNA7 (0.36) | CHRNA7CHRNB2CHRNA4SIGMAR1HTR2A | |
| SCHEMBL26880658 | 0.80 | CHRNA7 (0.36) | CHRNA7CHRNB2CHRNA4SIGMAR1HTR2A | |
| SCHEMBL26092188 | 0.78 | CHRNA7 (0.37) | CHRNA7CHRNB2CHRNA4SIGMAR1HTR2A | |
| SCHEMBL30296266 | 0.77 | CHRNA7 (0.36) | CHRNA7CHRNB2CHRNA4SIGMAR1HTR2A | |
| Hydrochloric Acid SCHEMBL30296463 | 0.77 | HTR2A (0.37) | CHRNA7CHRNB2CHRNA4SIGMAR1HTR2A | |
| SCHEMBL30296410 | 0.77 | CHRNA7 (0.34) | CHRNA7CHRNB2CHRNA4SIGMAR1GPR65 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4419203-A1 | TRICYCLIC GPR65 MODULATORS | Pathios Therapeutics Limited (GB) | 2024-08-28 | — | — | EP | disclosed |
| EP-4330258-A1 | COMPOUNDS | Pathios Therapeutics Limited (GB) | 2024-03-06 | — | — | EP | disclosed |
| US-20240051961-A1 | N-(PYRIDIN-2-YL)-6,7,8,9-TETRAHYDRO-5H-5,8-EPIMINOCYCLOHEPTA[C]PYRIDINE-10-CARBOXAMIDE DERIVATIVES AND SIMILAR COMPOUNDS AS GPR65 MODULATORS FOR THE TREATMENT OF CANCER | Pathios Therapeutics Limited (GB) | 2024-02-15 | — | — | US | disclosed |
| WO-2023067322-A1 | TRICYCLIC GPR65 MODULATORS | Pathios Therapeutics Limited (GB) | 2023-04-27 | — | — | WO | disclosed |
| WO-2022229615-A1 | COMPOUNDS | Pathios Therapeutics Limited (GB) | 2022-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240051961-A1 | N-(PYRIDIN-2-YL)-6,7,8,9-TETRAHYDRO-5H-5,8-EPIMINOCYCLOHEPTA[C]PYRIDINE-10-CARBOXAMIDE DERIVATIVES AND SIMILAR COMPOUNDS AS GPR65 MODULATORS FOR THE TREATMENT OF CANCER | GPR65, GPR68, GPR55 | CHRNA7 157/4885CHRNB2 182/4885CHRNA4 177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.